EXPERIENCE
THE REVEAL LINQ™
ADVANTAGE

Reveal LINQ™
Insertable Cardiac Monitor
with TruRhythm™ Detection

The world's smallest, most accurate ICM™

Medtronic
THE REVEAL LINQ™ SYSTEM ADVANTAGE

Actionable data to diagnose and treat even the most difficult-to-detect arrhythmias

UNMATCHED ACCURACY
Device innovations that provide leading detection accuracy

SUPERIOR EVIDENCE
Clinical rigor that guides decisions across multiple conditions

SIMPLIFIED MONITORING
Exclusive solutions that offer new freedom to focus on patients

SMALL
One-third the size of a AAA battery (1.2 cc)

SIMPLE
Minimally invasive, simplified insertion procedure

3 YEARS
Up to 3-year longevity for long-term monitoring

Reveal LINQ ICM
MR Conditional at 1.5 and 3.0 Tesla

MyCareLink™ Patient Monitor

CareLink™ Network and Reports

Revolution LINQ™ ICM with TruRhythm™ Detection

AN ADVANCED MONITORING SOLUTION

DEVICE LONGEVITY THAT OPTIMIZES DIAGNOSTIC YIELD

30%
Cryptogenic Stroke AF diagnoses occur after 2 years

20%
Syncope diagnoses occur after 2 years

Long-term, continuous data for ongoing AF management

20%
Syncpe diagnoses occur after 2 years

20%
Syncpe diagnoses occur after 2 years

20%
Syncpe diagnoses occur after 2 years
UNMATCHED ACCURACY

DRIVING ACCURACY EVOLUTION

Dedicated to advancing accuracy with every device generation.

INDUSTRY-LEADING TRURHYTHM DETECTION

Our newest detection algorithms streamline episodes without sacrificing sensitivity.

Smart filtering
NEW second sensing filter analyzes rhythms for possible undersensing in Brady and Pause

Self-learning
NEW AF algorithm learns and adapts to patients with sinus arrhythmia

SUPERIOR ACCURACY IN AF DETECTION

Demonstrating superior atrial fibrillation detection accuracy through our performance results.

Advanced AF detection*

<table>
<thead>
<tr>
<th></th>
<th>Reveal LINQ ICM</th>
<th>Confirm ICM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>98.9%</td>
<td>83.8%</td>
</tr>
<tr>
<td>PPV</td>
<td>99.0%</td>
<td>93.5%</td>
</tr>
</tbody>
</table>

AF BURDEN (Gross)

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity</th>
<th>PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioMonitor</td>
<td>99.7%</td>
<td>95.6%</td>
</tr>
<tr>
<td>Reveal LINQ</td>
<td>99.7%</td>
<td>95.3%</td>
</tr>
<tr>
<td>Reveal LINQ with TruRhythm Detection</td>
<td>99.7%</td>
<td>60.7%</td>
</tr>
</tbody>
</table>

AF EPISODE (Pt Avg)

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity</th>
<th>PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioMonitor</td>
<td>99.7%</td>
<td>95.6%</td>
</tr>
<tr>
<td>Reveal LINQ</td>
<td>99.7%</td>
<td>95.3%</td>
</tr>
<tr>
<td>Reveal LINQ with TruRhythm Detection</td>
<td>99.7%</td>
<td>60.7%</td>
</tr>
</tbody>
</table>

Streamlined Episode Review

8X fewer false positives 5,6

1% of False Positives = (1 –Episode PPV). Episode PPV may vary (gross, patient average).

*In known AF patients.
SUPERIOR EVIDENCE

MOST STUDIED
Evidence portfolio that includes 500+ published clinical articles and abstracts.

MOST VALIDATED
Clinical validation across Cryptogenic Stroke, Syncope, and Atrial Fibrillation.

MOST UTILIZED
Data leveraged by clinical societies to develop treatment guidelines across indications.

CRYPTOGENIC STROKE
CRYSTAL AF Study
Short- and intermediate-term cardiac monitoring may miss many patients with paroxysmal AF.
- 84 DAYS
  is the median time to AF detection in Cryptogenic Stroke patients
- 88%
  of patients who had AF would have been missed if only monitored for 30 days

2016 ESC Guidelines for the Management of AF
Long-term insertable cardiac monitoring recommended for cryptogenic stroke patients to document silent AF.

SYNCOPE
PICTURE Study
Reveal ICMs demonstrated success in diagnosing patients with unexplained syncope.
- 38%
  of patients experienced a recurrence within one year
- 78%
  of recurrent syncope patients had a Reveal ICM guided diagnosis

2017 ACC/AHA/HRS Guidelines for the Management of Syncope
Insertable cardiac monitoring recommended for syncope patients based on frequency and nature of events.

ATRIAL FIBRILLATION
Reveal AF Study
AF detection increases over time for patients at high risk for AF and stroke.
- 40%
  AF detection rate at 30 months
- 84.5%
  of patients with AF would have been missed if only monitored for 30 days
SIMPLIFIED MONITORING

FREEDOM TO FOCUS ON BETTER PATIENT CARE

Exclusive solutions keep you connected to your patients, while turning device data into actionable insights.

APP-BASED INSERTION WORK FLOW

Reveal LINQ Mobile Manager

Manage device registration, activation, CareLink™ pre-enrollment and patient education — right from your tablet.

MORE EFFICIENT DATA MANAGEMENT

Enhanced CareLink™ Network

Move critical transmissions to the forefront and assess/adjudicate episodes right from the improved Quick Look™ page.

A VIRTUAL EXTENSION OF YOUR CLINICAL TEAM

Reveal LINQ™ Monitoring Service

Streamline patient management with support from certified technicians who ensure ongoing data transmission, review cardiac data, and provide clinically actionable reports.
EXPERIENCE THE REVEAL LINQ™ ADVANTAGE

Reveal LINQ™
Insertable Cardiac Monitoring System
with TruRhythm™ Detection

UNMATCHED ACCURACY
SUPERIOR EVIDENCE
SIMPLIFIED MONITORING

The world's smallest, most accurate ICM

Medtronic and the Medtronic logo are trademarks of Medtronic. "Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company. Minneapolis, MN. All Rights Reserved.